½ÃÀ庸°í¼­
»óǰÄÚµå
1446477

Ç×ÀÀ°íÁ¦ ½ÃÀå - ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м® º¸°í¼­ : ¾àÁ¦ ºÐ·ùº°, Åõ¿© °æ·Îº°, ¿ëµµº°, Áö¿ªº°, ºÎ¹®º° ¿¹Ãø(2024-2030³â)

Anticoagulants Market Size, Share & Trends Analysis Report By Route of Administration, By Drug Category, By Application, By Region, And Segment Forecasts, 2024 - 2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Grand View Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 125 Pages | ¹è¼Û¾È³» : 2-10ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

Ç×ÀÀ°íÁ¦ ½ÃÀåÀÇ ¼ºÀå ¹× µ¿Çâ :

Grand View Research, Inc.ÀÇ ÃֽŠº¸°í¼­¿¡ µû¸£¸é ¼¼°èÀÇ Ç×ÀÀ°íÁ¦ ½ÃÀåÀº 2030³â±îÁö 604¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, 2024³âºÎÅÍ 2030³â±îÁöÀÇ ¿¹Ãø ±â°£ µ¿¾È CAGR 8.7%·Î È®´ëµÉ Àü¸ÁÀÔ´Ï´Ù.

ÀÌ ½ÃÀåÀº ÁÖ·Î ½ÉÇ÷°üÁúȯ(CVD)ÀÇ À¯º´·ü Áõ°¡ ¹× °í·ÉÈ­ Àα¸ Áõ°¡°¡ ¿øµ¿·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù. WHO¿¡ µû¸£¸é 2019³â CVD´Â ¼¼°è »ç¸ÁÀÇ ´ëºÎºÐÀ» ÀÏÀ¸Ä×À¸¸ç, »ç¸ÁÀÚ ¼ö´Â 1,790¸¸ ¸íÀ¸·Î, ÀÌ´Â ¼¼°è »ç¸ÁÀÚ ¼öÀÇ 32%¸¦ Â÷ÁöÇß½À´Ï´Ù. ÀÌ Áß 85%´Â ½ÉÀ帶ºñ¿Í ³úÁ¹Áß ¶§¹®À̾ú½À´Ï´Ù. ¶ÇÇÑ ºñÀü¿°¼º ÁúȯÀ¸·Î ÀÎÇÑ 1,700¸¸ ¸íÀÇ Á¶±â »ç¸Á Áß 38%°¡ CVD·Î ÀÎÇÑ °ÍÀ̾ú½À´Ï´Ù.

°Ô´Ù°¡, ¾É¾Æ Àֱ⸸ ÇÏ´Â ¶óÀÌÇÁ ½ºÅ¸ÀÏÀº ¿îµ¿ ºÎÁ·À¸·Î ÀÎÇÑ Ç÷ÀüÀÇ ¼¼°èÀûÀÎ Áõ°¡¿¡ Å©°Ô ±â¿©Çϰí ÀÖÀ¸¸ç, Ç×ÀÀ°íÁ¦ ¼ö¿ä¿¡ ¹ÚÂ÷¸¦ °¡Çϰí ÀÖ½À´Ï´Ù. ¿îµ¿ ºÎÁ·Àº Æó »öÀüÁõ(PE)°ú ½ÉºÎÁ¤¸Æ Ç÷ÀüÁõ(DVT)À» Æ÷ÇÔÇÑ Á¤¸Æ Ç÷Àü »öÀüÁõ(VTE)ÀÇ À§Çè »ó½Â°ú °ü·ÃÀÌ ÀÖ½À´Ï´Ù. DVT´Â ´Ù¸®ÀÇ ½ÉºÎÁ¤¸Æ¿¡ Ç÷ÀüÀÌ »ý±æ ¶§ ¹ß»ýÇϸç, PE´Â ½ÉºÎÁ¤¸Æ¿¡¼­ Æó·Î Ç÷ÀüÀÌ À̵¿ÇÒ ¶§ ¹ß»ýÇÕ´Ï´Ù. ¹Ì±¹ ±¹¸³ÀÇÇÐ µµ¼­°ü¿¡ µû¸£¸é, DVT¿Í PE¸¦ Æ÷ÇÔÇÑ VTE´Â ¹Ì±¹¿¡¼­ ¿¬°£ ¾à 90¸¸ ¸í¿¡ ¿µÇâÀ» ¹ÌÃÆ½À´Ï´Ù. ±× °á°ú ¼ö½Ê¸¸ ¸íÀÌ ÀÔ¿øÇÏ°í ¾à 30¸¸ ¸íÀÌ »ç¸ÁÇϰí ÀÖ½À´Ï´Ù. VTEÀÇ À¯º´·ü Áõ°¡ ¹× È¿°úÀûÀÎ Ä¡·á ¿É¼Ç¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡°¡ ½ÃÀåÀ» ¹Ð¾î¿Ã¸± °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

°Ô´Ù°¡ ±â¼ú Çõ½Å ÃËÁø, Ç×ÀÀ°íÁ¦ Ä¡·áÀÇ È¿´É ¹× ¾ÈÀü¼º Çâ»ó, ȯÀÚ ¸ð´ÏÅ͸µ ¹× °á°ú °³¼± µî Ç×ÀÀ°íÁ¦ ½ÃÀå Ȱ¼ºÈ­¿¡ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. â¾à ¹× ¾à¹° °³¹ßÀÇ ¹ßÀüÀ¸·Î ¹Ý°¨±â ¿¬Àå, ´Ù¸¥ ¾à¹°°úÀÇ »óÈ£ÀÛ¿ë °¨¼Ò, ÃâÇ÷ À§Çè °¨¼Ò µîÀÇ Æ¯¼ºÀÌ °³¼±µÈ ½Å±Ô Ç×ÀÀ°íÁ¦°¡ ¸¸µé¾îÁ³½À´Ï´Ù. ÀÌ »õ·Î¿î Ç×ÀÀ°íÁ¦´Â ȯÀÚ¿¡°Ô ´õ ¸¹Àº Ä¡·á ¿É¼ÇÀ» Á¦°øÇÏ°í ´õ ³ªÀº °á°ú¸¦ Á¦°øÇÕ´Ï´Ù. NIH¿¡ µû¸£¸é, À¯ÀüÀÚ Ä¡·á´Â Ç÷Àü Ä¡·á¸¦ À§ÇÑ »õ·Î¿î Á¢±Ù¹ýÀ̸ç, À¯ÀüÀÚ¸¦ ÀÌ¿ëÇÏ¿© Ç÷ÀüÀ» À¯¹ßÇÏ´Â ±Ùº»ÀûÀÎ À¯ÀüÀÚ °áÇÔÀ» ¼öÁ¤ÇÏ´Â °ÍÀÔ´Ï´Ù. ÀÌ Á¢±Ù¹ýÀº ¾ÆÁ÷ °³¹ßÀÇ Ãʱ⠴ܰ迡 ÀÖÁö¸¸, Ç÷Àü¿¡ ´ëÇÑ È¿°úÀûÀÎ Ä¡·á¹ýÀÌ µÉ °¡´É¼ºÀ» °¡Áö°í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, 2022³â 11¿ù, FDA´Â ÀÎÀÚ IX Á¦Á¦¸¦ ¿¹¹æÀûÀ¸·Î »ç¿ëÇÏ°í ½É°¢ÇÑ ÃâÇ÷À» ¹Ýº¹ÇÏ´Â Ç÷¿ìº´ BÀÇ ¼ºÀΠȯÀÚ¸¦ Ä¡·áÇÏ´Â À¯ÀüÀÚ Ä¡·áÁ¦ Hemgenix¸¦ ½ÂÀÎÇß½À´Ï´Ù. À̰ÍÀº Ç÷¾× ÀÀ°í ÀÎÀÚ IXÀÇ À¯ÀüÀÚ¸¦ °£¿¡ Åõ¿©ÇÏ´Â ÀÏȸ¼º À¯ÀüÀÚ Ä¡·áÀÔ´Ï´Ù.

Ç×ÀÀ°íÁ¦ ½ÃÀå º¸°í¼­ ÇÏÀ̶óÀÌÆ®

  • ½Å±Ô °æ±¸ Ç×ÀÀ°íÁ¦(NOAC)´Â 2023³â¿¡ ¾à¹° ¹üÁÖ ºÎ¹®À» Áö¹èÇÏ¿´À¸¸ç, »ç¿ë ÆíÀǼº ¹× ¸ð´ÏÅ͸µ Çʿ伺À» ÁÙ¿© Ä¡·á °èȹÀÇ ÁؼöÀ²À» Çâ»ó½ÃŰ´Â µ¥ ±â¿©Çß½À´Ï´Ù.
  • ÇìÆÄ¸° ¹× ÀúºÐÀÚ ÇìÆÄ¸°(LMWH) ºÎ¹®Àº ¿¹Ãø ±â°£ µ¿¾È °¡Àå ºü¸¥ CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
  • °æ±¸ ºÎ¹®Àº 2023³â ÃÖ´ë ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÏ¿´À¸¸ç, ¿¹Ãø ±â°£ µ¿¾È °¡Àå ºü¸¥ ¼ºÀåÀÌ ¿¹»óµË´Ï´Ù.
  • ¾É¾ÆÀÖ´Â ¶óÀÌÇÁ ½ºÅ¸ÀÏ, Èí¿¬·ü Áõ°¡ ¹× ´ë±â ¿À¿° Áõ°¡´Â ½ÉÇ÷°ü ÁúȯÀÇ À¯º´·ü Áõ°¡¿¡ ±â¿©ÇÕ´Ï´Ù.
  • ½É¹æ¼¼µ¿ ¹× ½É±Ù°æ»ö(½ÉÀå¹ßÀÛ)Àº ºÎÁ¤¸ÆÀÇ ¸ð´ÏÅ͸µ°ú °ü¸®ÀÇ Á߿伺ÀÌ ³ô¾ÆÁü¿¡ µû¶ó 2023³âÀÇ ¿ëµµ ºÎ¹®À» Áö¹èÇß½À´Ï´Ù.
  • ºÏ¹Ì´Â °í±Þ ÀÇ·á ÀÎÇÁ¶ó, ¾çÈ£ÇÑ ±ÔÁ¦ ȯ°æ, Ç×ÀÀ°í ¿ä¹ý¿¡ ´ëÇÑ ÀÏ¹Ý ½Ã¹ÎÀÇ ÀÇ½Ä Áõ°¡ µîÀÇ ¿äÀÎÀ¸·Î ½ÃÀåÀ» µ¶Á¡Çß½À´Ï´Ù.
  • 2022³â 2¿ù, FDA´Â Bayer AGÀÇ Ç×ÀÀ°íÁ¦ Asundexian(BAY2433334)¸¦ Fast-Track ÁöÁ¤Çß½À´Ï´Ù. ÀÌ °æ±¸ Ç÷¾× ÀÀ°í ÀÎÀÚ Xla ¾ïÁ¦Á¦´Â ºñ ½ÉÀå »öÀü ¼º ÇãÇ÷¼º ³úÁ¹Áß, ½É¹æ ¼¼µ¿ ¶Ç´Â ÃÖ±Ù¿¡´Â ½É±Ù °æ»ö ȯÀÚ¿¡¼­ 2 Â÷ Ç÷ÀüÁõÀ» ¿¹¹æÇϱâ À§ÇØ ÇöÀç 2»ó ¿¬±¸°¡ ÁøÇà ÁßÀÔ´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý ¹× ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå Ç×ÀÀ°íÁ¦ ½ÃÀå : º¯¼ö, µ¿Çâ ¹× ¹üÀ§

  • ½ÃÀå °èÅë Àü¸Á
    • »óÀ§ ½ÃÀå Àü¸Á
    • °ü·Ã ¹× ºÎ¼ö ½ÃÀå Àü¸Á
  • ½ÃÀå ¿ªÇÐ
    • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ ºÐ¼®
    • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ ºÐ¼®
  • Ç×ÀÀ°íÁ¦ ½ÃÀå ºÐ¼® Åø
    • ¾÷°è ºÐ¼®-Porter's Five Forces ºÐ¼®
    • PESTEL ºÐ¼®

Á¦4Àå Ç×ÀÀ°íÁ¦ ½ÃÀå : ¾àÁ¦ ºÐ·ùº° ÃßÁ¤ ¹× µ¿Ç⠺м®

  • ¾àÁ¦ ºÐ·ùº° ½ÃÀå Á¡À¯À²(2023³â, 2030³â)
  • ºÎ¹® ´ë½Ãº¸µå
  • ¾àÁ¦ ºÐ·ùº° ¼¼°èÀÇ Ç×ÀÀ°íÁ¦ ½ÃÀå Àü¸Á
  • ½ÃÀå ±Ô¸ð, ¿¹Ãø ¹× µ¿Ç⠺м®(2018-2030³â)

Á¦5Àå Ç×ÀÀ°íÁ¦ ½ÃÀå : Åõ¿© °æ·Îº° ÃßÁ¤ ¹× µ¿Ç⠺м®

  • Åõ¿© °æ·Îº° ½ÃÀå Á¡À¯À²(2023³â,2030³â)
  • ºÎ¹® ´ë½Ãº¸µå
  • Åõ¿© °æ·Îº° ¼¼°èÀÇ Ç×ÀÀ°íÁ¦ ½ÃÀå Àü¸Á
  • ½ÃÀå ±Ô¸ð, ¿¹Ãø ¹× µ¿Ç⠺м®(2018-2030³â)

Á¦6Àå Ç×ÀÀ°íÁ¦ ½ÃÀå : ¿ëµµº° ÃßÁ¤ ¹× µ¿Ç⠺м®

  • ¿ëµµº° ½ÃÀå Á¡À¯À²(2023³â, 2030³â)
  • ºÎ¹® ´ë½Ãº¸µå
  • ¿ëµµº° ¼¼°èÀÇ Ç×ÀÀ°íÁ¦ ½ÃÀå Àü¸Á
  • ½ÃÀå ±Ô¸ð, ¿¹Ãø ¹× µ¿Ç⠺м®(2018-2030³â)

Á¦7Àå Ç×ÀÀ°íÁ¦ ½ÃÀå : Áö¿ªº° ÃßÁ¤ ¹× µ¿Ç⠺м®

  • Áö¿ªº° ½ÃÀå Á¡À¯À² ºÐ¼®(2023³â, 2030³â)
  • Áö¿ªº° ½ÃÀå ´ë½Ãº¸µå
  • ¼¼°è Áö¿ª ½ÃÀå ÇöȲ
  • ½ÃÀå ±Ô¸ð, ¿¹Ãø ¹× µ¿Ç⠺м®(2018-2030³â)
  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
  • À¯·´
    • ¿µ±¹
    • µ¶ÀÏ
    • ÇÁ¶û½º
    • ÀÌÅ»¸®¾Æ
    • ½ºÆäÀÎ
    • ³ë¸£¿þÀÌ
    • ½º¿þµ§
    • µ§¸¶Å©
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • ÀϺ»
    • Áß±¹
    • Àεµ
    • È£ÁÖ
    • Çѱ¹
    • ű¹
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
    • ¾Æ¸£ÇîÆ¼³ª
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • ³²¾ÆÇÁ¸®Ä«
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
    • Äí¿þÀÌÆ®

Á¦8Àå °æÀï ±¸µµ

  • ÁÖ¿ä ½ÃÀå ÁøÃâ±â¾÷º° ÃÖ±ÙÀÇ µ¿Çâ ¹× ¿µÇ⠺м®
  • ȸ»ç ¹× °æÀïÀÇ ºÐ·ù
  • º¥´õ »óȲ
    • Aspen Holdings
    • Pfizer Inc.
    • Bristol-Myers Squibb Company
    • GSK plc
    • Sanofi
    • Bayer AG
    • Boehringer Ingelheim International GmbH
    • DAIICHI SANKYO COMPANY, LIMITED
    • Johnson &Johnson Services, Inc.
    • Eisai Co., Ltd.
AJY 24.03.21

Anticoagulants Market Growth & Trends:

The global anticoagulants market is anticipated to reach USD 60.4 billion by 2030 and is expected to expand at a CAGR of 8.7% during the forecast period of 2024 to 2030, according to a new report by Grand View Research, Inc. The market is primarily driven by the increasing prevalence of cardiovascular diseases (CVDs) and growing aging population. According to WHO, in 2019, CVDs caused majority of deaths worldwide, accounting for 17.9 million fatalities, which is 32% of global deaths. Among these deaths, 85% were attributed to heart attack and stroke. Moreover, of the 17 million premature deaths caused by noncommunicable diseases, 38% were due to CVDs in the same year.

Moreover, sedentary lifestyles significantly contribute to the global rise of blood clots owing to physical inactivity, fueling the demand for anticoagulants. Physical inactivity has been linked to an increased risk of venous thromboembolism (VTE), a condition that encompasses pulmonary embolism (PE) and deep vein thrombosis (DVT). The condition arises when a blood clot occurs in a deep vein in the legs, while PE occurs when a blood clot travels from a deep vein to the lungs. As per the National Library of Medicine, VTE, which includes DVT and PE, impacts around 900,000 individuals in the U.S. annually. This led to several hundred thousand hospitalizations and approximately 300,000 deaths. The increasing prevalence of VTE and the growing demand for effective treatment options is expected to boost the market.

Furthermore, technological advancements are playing a significant role in boosting the anticoagulants market by driving innovation, improving the efficacy and safety of anticoagulant treatments, and enhancing patient monitoring and outcomes. Advancements in drug discovery and development have led to the creation of new anticoagulants with improved properties, such as longer half-lives, fewer interactions with other medications, and reduced bleeding risks. These novel anticoagulants offer patients more treatment options and better outcomes. According to NIH, gene therapy is a new approach for treatment of blood clots that involves the use of genes to correct the underlying genetic defect that causes clotting. This approach is still in its early stage of development but has potential to be an effective treatment for blood clots. For instance, in November 2022, the FDA approved Hemgenix, a gene therapy to treat adults with hemophilia B who are using Factor IX prophylaxis and have a history of repeated, serious bleeding episodes. It is a one-time gene therapy that delivers a gene for clotting factor IX to the liver.

Anticoagulants Market Report Highlights:

  • Novel oral anticoagulants (NOACs) dominated the drug category segment in 2023 owing to their ease of use and reduced need for monitoring, contributing to better adherence to treatment plans
  • The Heparin and Low Molecular Weight Heparin (LMWH) segment is expected to grow at the fastest CAGR over the forecast period.
  • The oral segment held the largest market share in 2023 and is expected to witness fastest growth over the forecast period.
  • Sedentary lifestyle, increasing incidence of smoking, and rising air pollution are contributing to the growing prevalence of cardiovascular diseases
  • Atrial fibrillation/myocardial infarction (Heart attack) dominated the application segment in 2023 owing to rising importance of monitoring and managing arrhythmia
  • North America dominated the market owing to factors such as advanced healthcare infrastructure, favorable regulatory environment and rising public awareness of anticoagulant therapy
  • In February 2022, FDA granted Bayer AG's anticoagulant Asundexian (BAY2433334) Fast-Track designation. The oral factor Xla inhibitor is currently undergoing phase 2 trials for the potential prevention of secondary thrombosis in patients with non-cardioembolic ischemic stroke, atrial fibrillation, or more recently myocardial infarction.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Drug category
    • 1.2.2. Route of administration
    • 1.2.3. Application
  • 1.3. Regional scope
  • 1.4. Estimates and forecasts timeline
  • 1.5. Research Methodology
  • 1.6. Information Procurement
    • 1.6.1. Purchased database
    • 1.6.2. GVR's internal database
    • 1.6.3. Secondary sources
    • 1.6.4. Primary research
    • 1.6.5. Details of primary research
      • 1.6.5.1. Data for primary interviews in North America
      • 1.6.5.2. Data for primary interviews in Europe
      • 1.6.5.3. Data for primary interviews in Asia Pacific
      • 1.6.5.4. Data for primary interviews in Latin America
      • 1.6.5.5. Data for Primary interviews in MEA
  • 1.7. Information or Data Analysis
    • 1.7.1. Data analysis models
  • 1.8. Market Formulation & Validation
  • 1.9. Model Details
    • 1.9.1. Commodity flow analysis (Model 1)
    • 1.9.2. Approach 1: Commodity flow approach
    • 1.9.3. Volume price analysis (Model 2)
    • 1.9.4. Approach 2: Volume price analysis
  • 1.10. List of Secondary Sources
  • 1.11. List of Primary Sources
  • 1.12. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Technology outlook
    • 2.2.2. Treatment outlook
    • 2.2.3. Application outlook
    • 2.2.4. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Anticoagulants Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Increasing prevalence of chronic diseases
      • 3.2.1.2. Technological advancements in development of anticoagulant products
      • 3.2.1.3. Growing adoption of Novel Oral Anticoagulants (NOACs)
      • 3.2.1.4. Rising geriatric population and increase prevalence of obesity
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. High price associated with Novel Oral Anticoagulants (NOACs)
      • 3.2.2.2. Stringent government regulations and poor demand in underdeveloped countries
  • 3.3. Anticoagulants Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's Five Forces
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. Anticoagulants Market: Drug Category Estimates & Trend Analysis

  • 4.1. Drug Category Market Share, 2023 & 2030
  • 4.2. Segment Dashboard
  • 4.3. Global Anticoagulants Market by Drug Category Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 4.4.1. Novel oral anticoagulants (NOACs)
      • 4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.2. Eliquis
      • 4.4.1.3. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.4. Xarelto
      • 4.4.1.5. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.6. Savaysa & Lixiana
      • 4.4.1.7. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.8. Pradaxa
      • 4.4.1.9. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2. Heparin and Low Molecular Weight Heparin (LMWH)
      • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.3. Vitamin k Antagonist
      • 4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.4. Direct thrombin inhibitors
      • 4.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.5. Others
      • 4.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Anticoagulants Market: Route of Administration Estimates & Trend Analysis

  • 5.1. Route of Administration Market Share, 2023 & 2030
  • 5.2. Segment Dashboard
  • 5.3. Global Anticoagulants Market by Treatment Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 5.4.1. Oral anticoagulants
      • 5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.2. Injectable anticoagulants
      • 5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Anticoagulants Market: Application Estimates & Trend Analysis

  • 6.1. Application Market Share, 2023 & 2030
  • 6.2. Segment Dashboard
  • 6.3. Global Anticoagulants Market by Application Outlook
  • 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 6.4.1. Atrial Fibrillation/Myocardial Infarction (Heart Attack)
      • 6.4.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
    • 6.4.2. Deep Vein Thrombosis (DVT)
      • 6.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.3. Pulmonary Embolism
      • 6.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.4. Others
      • 6.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Anticoagulants Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2023 & 2030
  • 7.2. Regional Market Dashboard
  • 7.3. Global Regional Market Snapshot
  • 7.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 7.5. North America
    • 7.5.1. U.S.
      • 7.5.1.1. Key country dynamics
      • 7.5.1.2. Regulatory framework/ reimbursement structure
      • 7.5.1.3. Competitive scenario
      • 7.5.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.2. Canada
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Regulatory framework/ reimbursement structure
      • 7.5.2.3. Competitive scenario
      • 7.5.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. Europe
    • 7.6.1. UK
      • 7.6.1.1. Key country dynamics
      • 7.6.1.2. Regulatory framework/ reimbursement structure
      • 7.6.1.3. Competitive scenario
      • 7.6.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.2. Germany
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Regulatory framework/ reimbursement structure
      • 7.6.2.3. Competitive scenario
      • 7.6.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.3. France
      • 7.6.3.1. Key country dynamics
      • 7.6.3.2. Regulatory framework/ reimbursement structure
      • 7.6.3.3. Competitive scenario
      • 7.6.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.4. Italy
      • 7.6.4.1. Key country dynamics
      • 7.6.4.2. Regulatory framework/ reimbursement structure
      • 7.6.4.3. Competitive scenario
      • 7.6.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.5. Spain
      • 7.6.5.1. Key country dynamics
      • 7.6.5.2. Regulatory framework/ reimbursement structure
      • 7.6.5.3. Competitive scenario
      • 7.6.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.6. Norway
      • 7.6.6.1. Key country dynamics
      • 7.6.6.2. Regulatory framework/ reimbursement structure
      • 7.6.6.3. Competitive scenario
      • 7.6.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.7. Sweden
      • 7.6.7.1. Key country dynamics
      • 7.6.7.2. Regulatory framework/ reimbursement structure
      • 7.6.7.3. Competitive scenario
      • 7.6.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.8. Denmark
      • 7.6.8.1. Key country dynamics
      • 7.6.8.2. Regulatory framework/ reimbursement structure
      • 7.6.8.3. Competitive scenario
      • 7.6.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7. Asia Pacific
    • 7.7.1. Japan
      • 7.7.1.1. Key country dynamics
      • 7.7.1.2. Regulatory framework/ reimbursement structure
      • 7.7.1.3. Competitive scenario
      • 7.7.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.2. China
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Regulatory framework/ reimbursement structure
      • 7.7.2.3. Competitive scenario
      • 7.7.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.3. India
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Regulatory framework/ reimbursement structure
      • 7.7.3.3. Competitive scenario
      • 7.7.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.4. Australia
      • 7.7.4.1. Key country dynamics
      • 7.7.4.2. Regulatory framework/ reimbursement structure
      • 7.7.4.3. Competitive scenario
      • 7.7.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.5. South Korea
      • 7.7.5.1. Key country dynamics
      • 7.7.5.2. Regulatory framework/ reimbursement structure
      • 7.7.5.3. Competitive scenario
      • 7.7.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.6. Thailand
      • 7.7.6.1. Key country dynamics
      • 7.7.6.2. Regulatory framework/ reimbursement structure
      • 7.7.6.3. Competitive scenario
      • 7.7.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.8. Latin America
    • 7.8.1. Brazil
      • 7.8.1.1. Key country dynamics
      • 7.8.1.2. Regulatory framework/ reimbursement structure
      • 7.8.1.3. Competitive scenario
      • 7.8.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.8.2. Mexico
      • 7.8.2.1. Key country dynamics
      • 7.8.2.2. Regulatory framework/ reimbursement structure
      • 7.8.2.3. Competitive scenario
      • 7.8.2.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.8.3. Argentina
      • 7.8.3.1. Key country dynamics
      • 7.8.3.2. Regulatory framework/ reimbursement structure
      • 7.8.3.3. Competitive scenario
      • 7.8.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.9. MEA
    • 7.9.1. South Africa
      • 7.9.1.1. Key country dynamics
      • 7.9.1.2. Regulatory framework/ reimbursement structure
      • 7.9.1.3. Competitive scenario
      • 7.9.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.9.2. Saudi Arabia
      • 7.9.2.1. Key country dynamics
      • 7.9.2.2. Regulatory framework/ reimbursement structure
      • 7.9.2.3. Competitive scenario
      • 7.9.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.9.3. UAE
      • 7.9.3.1. Key country dynamics
      • 7.9.3.2. Regulatory framework/ reimbursement structure
      • 7.9.3.3. Competitive scenario
      • 7.9.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.9.4. Kuwait
      • 7.9.4.1. Key country dynamics
      • 7.9.4.2. Regulatory framework/ reimbursement structure
      • 7.9.4.3. Competitive scenario
      • 7.9.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Company/Competition Categorization
  • 8.3. Vendor Landscape
    • 8.3.1. List of key distributors and channel partners
    • 8.3.2. Key customers
    • 8.3.3. Key company market share analysis, 2023
    • 8.3.4. Aspen Holdings
      • 8.3.4.1. Company overview
      • 8.3.4.2. Financial performance
      • 8.3.4.3. Product benchmarking
      • 8.3.4.4. Strategic initiatives
    • 8.3.5. Pfizer Inc.
      • 8.3.5.1. Company overview
      • 8.3.5.2. Financial performance
      • 8.3.5.3. Product benchmarking
      • 8.3.5.4. Strategic initiatives
    • 8.3.6. Bristol-Myers Squibb Company
      • 8.3.6.1. Company overview
      • 8.3.6.2. Financial performance
      • 8.3.6.3. Product benchmarking
      • 8.3.6.4. Strategic initiatives
    • 8.3.7. GSK plc
      • 8.3.7.1. Company overview
      • 8.3.7.2. Financial performance
      • 8.3.7.3. Product benchmarking
      • 8.3.7.4. Strategic initiatives
    • 8.3.8. Sanofi
      • 8.3.8.1. Company overview
      • 8.3.8.2. Financial performance
      • 8.3.8.3. Product benchmarking
      • 8.3.8.4. Strategic initiatives
    • 8.3.9. Bayer AG
      • 8.3.9.1. Company overview
      • 8.3.9.2. Financial performance
      • 8.3.9.3. Product benchmarking
      • 8.3.9.4. Strategic initiatives
    • 8.3.10. Boehringer Ingelheim International GmbH
      • 8.3.10.1. Company overview
      • 8.3.10.2. Financial performance
      • 8.3.10.3. Product benchmarking
      • 8.3.10.4. Strategic initiatives
    • 8.3.11. DAIICHI SANKYO COMPANY, LIMITED
      • 8.3.11.1. Company overview
      • 8.3.11.2. Financial performance
      • 8.3.11.3. Product benchmarking
      • 8.3.11.4. Strategic initiatives
    • 8.3.12. Johnson & Johnson Services, Inc.
      • 8.3.12.1. Company overview
      • 8.3.12.2. Financial performance
      • 8.3.12.3. Product benchmarking
      • 8.3.12.4. Strategic initiatives
    • 8.3.13. Eisai Co., Ltd.
      • 8.3.13.1. Company overview
      • 8.3.13.2. Financial performance
      • 8.3.13.3. Product benchmarking
      • 8.3.13.4. Strategic initiatives
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦